1. Home
  2. LGIH vs MLTX Comparison

LGIH vs MLTX Comparison

Compare LGIH & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LGI Homes Inc.

LGIH

LGI Homes Inc.

HOLD

Current Price

$55.73

Market Cap

1.2B

ML Signal

HOLD

Logo MoonLake Immunotherapeutics

MLTX

MoonLake Immunotherapeutics

HOLD

Current Price

$18.60

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LGIH
MLTX
Founded
2003
2021
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Homebuilding
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.1B
IPO Year
2013
2020

Fundamental Metrics

Financial Performance
Metric
LGIH
MLTX
Price
$55.73
$18.60
Analyst Decision
Hold
Buy
Analyst Count
5
9
Target Price
$75.90
$22.44
AVG Volume (30 Days)
322.7K
1.1M
Earning Date
05-20-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
3.12
N/A
Revenue
$1,705,504,000.00
N/A
Revenue This Year
$18.38
N/A
Revenue Next Year
$7.73
N/A
P/E Ratio
$17.78
N/A
Revenue Growth
N/A
N/A
52 Week Low
$39.70
$5.95
52 Week High
$77.38
$62.75

Technical Indicators

Market Signals
Indicator
LGIH
MLTX
Relative Strength Index (RSI) 47.89 61.77
Support Level $58.78 $15.27
Resistance Level $63.66 $18.90
Average True Range (ATR) 2.96 0.86
MACD -0.67 0.21
Stochastic Oscillator 33.14 72.77

Price Performance

Historical Comparison
LGIH
MLTX

About LGIH LGI Homes Inc.

LGI Homes Inc is engaged in the design, construction, and sale of new homes in markets. The company current product offerings include entry-level homes, including both detached homes and townhomes, and move-up homes sold, which are sold under LGI Homes brand, and luxury series homes, which are sold under the Terrata Homes brand. It offers a set number of floor plans in each community with features that include upgrades, such as granite countertops, appliances, and ceramic tile flooring. The company have seven operating segments ( West, Northwest, Central, Midwest, Florida, Southeast and Mid-Atlantic) that it aggregates into five qualifying reportable segment. Majority of the revenue is generated from Central division segment.

About MLTX MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.

Share on Social Networks: